ArticleJournal of clinical research in pediatric endocrinology2026
Hereditary Hypophosphatemic Rickets with Hypercalciuria-Importance of Further Evaluation when Clinical Suspicion is Strong
Article in Journal of clinical research in pediatric endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hereditary hypophosphatemic rickets with hypercalciuria (HHRH) is a rare genetic condition with autosomal recessive inheritance and a prevalence of 1 in 250000. It is due to mutation of the SLC4A3 gene. Correct diagnosis of this condition is important as treatment with active vitamin D metabolites is contraindicated. Evolution of the disease despite initial completely normal biochemistry has been observed, potentially creating diagnostic confusion. The first child presented at the age of 5.5 years with features of rickets. He had an abnormal bone profile with normal vitamin D levels. Urinary phosphate studies were compatible with HHRH. He was treated with phosphate supplementation and potassium citrate. He has well responded well to treatment. The second child initially presented at 1.5 years of age with leg bowing and a family history of hypercalciuria. All investigation findings, including urinary phosphate studies, were within normal limits. At the age of 2.5 years, he again presented with worsening of bowing. Biochemical and urinary investigations were repeated and laboratory findings were now compatible with HHRH. These cases highlight the importance of repeated investigations despite initial normal parameters, if the initial clinical suspicion is strong. Clinical- and investigation-based diagnosis of this rare genetic disease, HHRH, is feasible in resource limited setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.